Shanghai Fosun Pharmaceutical : OVERSEAS REGULATORY ANNOUNCEMENT (H SHARES)

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the ''Announcement in Relation to Acceptance of a Subsidiary's Drug Registration Application'' published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

6 January 2022

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang, Mr. Wang Kexin and Ms. Guan Xiaohui; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

• for identification purposes only

Stock code: 600196	Stock abbreviation: Fosun Pharma	Announcement No.: Lin 2022-005
Bond code: 143020	Bond abbreviation: 17 Fosun 01
Bond code: 143422	Bond abbreviation: 18 Fosun 01
Bond code: 155067	Bond abbreviation: 18 Fosun 02
Bond code: 155068	Bond abbreviation: 18 Fosun 03
Bond code: 175708	Bond abbreviation: 21 Fosun 01

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to Acceptance of a Subsidiary's Drug Registration Application

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, the drug registration application of Tranexamic Acid Injection (the "New

Drug") developed by Jinzhou Aohong Pharmaceutical Co., Ltd*（錦州奧鴻藥業有限責

任公司） ("Aohong Pharma"), a subsidiary of Shanghai Fosun Pharmaceutical (Group)

Co., Ltd.* (the "Company"), which is used for the treatment of hemorrhage caused by the Systemic Hyperfibrinolysis and abnormal hemorrhage caused by Local Hyperfibrinolysis, was accepted by the National Medical Products Administration (the "NMPA").

II. Basic Information and Research Progress of the New Drug

The New Drug is a chemical drug independently developed by Aohong Pharma, which is intended to be mainly used for: (1) hemorrhage caused by Systemic Hyperfibrinolysis, such as leukemia, aplastic anemia and purpura, as well as abnormal hemorrhage during and after surgery; (2) abnormal hemorrhage caused by Local

1

Hyperfibrinolysis, such as pulmonary hemorrhage, nasal hemorrhage, genital hemorrhage, renal hemorrhage, abnormal hemorrhage during and after prostate surgery.

As at the date of this announcement, Tranexamic Acid Injection approved for market launch in the PRC (excluding Hong Kong, Macau and Taiwan for the purpose of this announcement) mainly includes Transamin® of Shanxi Powerdone Pharmaceutics Co.,

Ltd.*, Shengjining (聖濟寧)® of Guizhou Shengjitang Pharmaceutical Co., Ltd.* (貴州

聖濟堂製藥有限公司), and Suning (速寧)® of Hunan Dongting Pharmaceutical Co.,

Ltd.* (湖南洞庭藥業股份有限公司). According to the latest data of IQVIA CHPA

provided by IQVIA, the sales of Tranexamic Acid Injection in the PRC in 2020 amounted to approximately RMB673 million. IQVIA is the world's leading provider of professional information in respect of medical and health industry and strategic consulting services and the data of IQVIA CHPA represents the data of pharmaceutical sales market targeting hospitals with more than 100 beds in the PRC, and the actual sales of different pharmaceutical products may differ to a different extent from the data of IQVIA CHPA due to different distribution channels.

As of November 2021, Aohong Pharma has invested approximately RMB5.55 million (unaudited) in the research and development of the New Drug at this stage.

III. Risk Warning

The commercialization and production of the New Drug is conditional upon mainly, among other things, the passing of GMP compliance inspection and the obtainment of drug approval number. This acceptance of the drug registration application will not have a material impact on the current results of the Group (i.e. the Company and its subsidiaries/units).

Due to the industry characteristics inherent to pharmaceutical products, the specific sales after the market launch of pharmaceutical products may be affected by factors including but not limited to the market condition and sales channels, which is subject to great uncertainty. Investors are advised to pay attention to investment risks.

2

Announcement is hereby given.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 6 January 2022

3